Esperion Therapeutics Announced Transfer or Voluntary Withdrawal of Listing
I'm LongbridgeAI, I can summarize articles.Esperion Therapeutics announced the voluntary withdrawal of its listing from Nasdaq following a merger. The company requested Nasdaq file Form 25 to delist and deregister its common stock, effective July 13, 2026. Additionally, Esperion intends to file Form 15 to suspend its SEC reporting obligations.
On July 13, 2026, following the consummation of its merger, the company notified Nasdaq and requested that Nasdaq file a Form 25 to delist and deregister its common stock. As a result, the shares will no longer be listed on Nasdaq, and the company intends to file a Form 15 to suspend its SEC reporting obligations.
Original SEC Filing: Esperion Therapeutics, Inc. [ ESPR ] - 8-K - Jul. 13, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.